Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06936878 · ClinicalTrials.gov registry record · NA

BOLSTER: Learning New Skills to Thrive

A NA study of Advanced Cancer and Gynecologic Cancer, sponsored by Dana-Farber Cancer Institute.

Recruiting
Registry status
NA
Development phase
600
Enrollment target
2
Study locations

NCT06936878: Recruiting NA study of Advanced Cancer and Gynecologic Cancer, sponsored by Dana-Farber Cancer Institute.

NCT06936878 is a NA study of Advanced Cancer and Gynecologic Cancer that is actively recruiting participants, run by Dana-Farber Cancer Institute. The registered enrollment target is 600 participants, above the 241-participant average among 122 other Advanced Cancer trials with a reported enrollment target (149% higher). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06936878, a NA study of Advanced Cancer and Gynecologic Cancer, is actively recruiting participants, sponsored by Dana-Farber Cancer Institute.

RECRUITING
Registry status
NA
Development phase
600 participants
Enrollment target
2
Study locations

Study Summary

This research study is evaluating a new program called Building Out Lifelines for Safety, Trust, Empowerment, and Renewal or (BOLSTER), which was designed to support participants with a gynecological or gastrointestinal cancer and new and complex care needs.

Primary Outcome

Assessed by the FACT-G, a 27-item scale designed to measure physical, emotional, social, functional, and family well-being in patients with life-limiting cancer. Answers are rated on a 5-point Likert scale from 0 "Not At All" to 4 "Very Much" with a total scores range of 0 to 108. Higher scores indicate better quality of life.

Interventions

  • BEHAVIORAL BOLSTER Program

Study Locations (2)

Massachusetts

  • Dana-Farber Cancer Institute - Boston

Texas

  • The University of Texas MD Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 600 participants
Start Date 2025-05-12
Est. Completion 2028-02-29
Phase NA
Dana-Farber Cancer Institute

781 total trials

What NCT06936878 shows while recruiting

NCT06936878 is an interventional study that assigns participants to a tested intervention. The registered 600 participants enrollment target is mid-sized for trials with a published cap, above the 241-participant average among 122 other Advanced Cancer trials with a reported enrollment target (149% higher).

The record links to 3 conditions, with Advanced Cancer appearing as the primary indexed condition, and to 1 intervention - of which BOLSTER Program is the first listed.

NCT06936878 reports a single indexed study location in Massachusetts, Texas.

Frequently Asked Questions

What is clinical trial NCT06936878 about?

NCT06936878 is a clinical study titled "BOLSTER: Learning New Skills to Thrive". This research study is evaluating a new program called Building Out Lifelines for Safety, Trust, Empowerment, and Renewal or (BOLSTER), which was designed to support participants with a gynecological or gastrointestinal cancer and new and complex care needs.

What is the current status of trial NCT06936878?

This trial is currently recruiting. It is a NA study. The enrollment target is 600 participants. The study started on 2025-05-12. Estimated completion is 2028-02-29.

What conditions does trial NCT06936878 study?

This clinical trial studies the following conditions: Advanced Cancer, Gynecologic Cancer, Gastrointestinal Cancer.

What interventions are being tested in trial NCT06936878?

The interventions under investigation include: BOLSTER Program (BEHAVIORAL).

Who is sponsoring clinical trial NCT06936878?

This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06936878 being conducted?

This trial has 2 study locations across Massachusetts, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Advanced Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06936878's enrollment target sits among peer trials

600 5th of 122 higher than 118 of 122 other Advanced Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Advanced Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00004317 · 600 participants · Phase 4

    Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis

  • NCT00209235 · 600 participants · NA

    Albright Hereditary Osteodystrophy: Natural History, Growth, and Cognitive/Behavioral Assessments

  • NCT01473784 · 600 participants · NA

    Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck

  • NCT01866371 · 600 participants

    High Resolution Retinal Imaging

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06936878, the US trial registry maintained by the National Library of Medicine. NCT06936878 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.